![]() | Up a level |
Journal Article
Demir, Munevver, Phiri, Sam, Heger, Eva, Heller, Tom, Kaiser, Rolf, Chaweza, Thom, Faetkenheuer, Gerd, Steffen, Hans-Michael and Neuhann, Florian (2018). Prevalence of Anti-HBs Without Anti-HBc Among HIV-Infected Adults Initiating Antiretroviral Therapy in Lilongwe, Malawi. JAIDS, 78 (3). S. E14 - 2. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1077-9450
Krawczyk, Marcin ORCID: 0000-0002-0113-0777, Rau, Monika
ORCID: 0000-0003-1219-4044, Schattenberg, Jorn M.
ORCID: 0000-0002-4224-4703, Bantel, Heike, Pathil, Anita, Demir, Munevver, Kluwe, Johannes, Boettler, Tobias
ORCID: 0000-0002-1195-055X, Lammert, Frank and Geier, Andreas
(2017).
Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
J. Lipid Res., 58 (1).
S. 247 - 256.
BETHESDA:
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC.
ISSN 1539-7262
Loosen, Sven H., Schulze-Hagen, Max, Vucur, Mihael, Gorgulho, Joao, Paffenholz, Pia, Benz, Fabian, Mohr, Raphael, Demir, Munevver ORCID: 0000-0002-7050-797X, Wree, Alexander
ORCID: 0000-0002-2968-1335, Kuhl, Christiane, Trautwein, Christian, Tacke, Frank, Bruners, Philipp
ORCID: 0000-0002-5790-3687, Luedde, Tom and Roderburg, Christoph
(2021).
Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis.
JGH Open, 5 (3).
S. 356 - 364.
HOBOKEN:
WILEY.
ISSN 2397-9070
Traussnigg, Stefan, Schattenberg, Jorn M. ORCID: 0000-0002-4224-4703, Demir, Munevver, Wiegand, Johannes, Geier, Andreas, Teuber, Gerfinde, Hofmann, Wolf Peter, Kremer, Andreas E., Spreda, Frank, Kluwe, Johannes, Petersen, Jorg, Boettler, Tobias
ORCID: 0000-0002-1195-055X, Rainer, Florian, Halilbasic, Emina, Greinwald, Roland, Prols, Markus, Manns, Michael P., Fickert, Peter and Trauner, Michael
ORCID: 0000-0002-1275-6425
(2019).
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
Lancet Gastroenterol. Hepatol., 4 (10).
S. 781 - 794.
SAN DIEGO:
ELSEVIER INC.
ISSN 2468-1253